RCM
PCRX icon

Radcliffe Capital Management’s Pacira BioSciences PCRX Stock Holding History

Radcliffe Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39,831
Closed -$1.03M – 409
2025
Q4 		$1.03M Sell
39,831
-7,758
-16% -$184K 0.06% 191
2025
Q3 		$1.23M Buy
+47,589
New +$1.17M 0.08% 149

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Radcliffe Capital Management's PCRX Position: Q1 2026 in Review

Radcliffe Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 39,831 shares — an estimated $1.03M sold.

Radcliffe Capital Management first reported a position in PCRX in Q3 2025 and held it in 2 quarters. The position peaked at $1.23M in Q3 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Radcliffe Capital Management reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
  • Radcliffe Capital Management sold 39,831 Pacira BioSciences shares in Q1 2026, an estimated $1.03M.
  • Radcliffe Capital Management first reported a position in Pacira BioSciences in Q3 2025 and held it in 2 quarters.
  • Radcliffe Capital Management's Pacira BioSciences position peaked at $1.23M in Q3 2025.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Radcliffe Capital Management's 13F filing for Q1 2026, filed 15 May 2026.